keyword
MENU ▼
Read by QxMD icon Read
search

basdai

keyword
https://www.readbyqxmd.com/read/28748512/cross-cultural-adaptation-and-validation-of-the-chinese-version-of-the-health-assessment-questionnaire-for-the-spondyloarthropathies-haq-s
#1
DeLin Liu, Chen Zhang, Chen Wang, Jiao Liu, DaHe Li, Jia Li, Weidong Xu
The Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) is a commonly used questionnaire to evaluate function and health status of patients with ankylosing spondylitis (AS). The objective of this study was to cross-culturally adapt the HAQ-S into Chinese and then to evaluate its reliability and validity. The Chinese version of the HAQ-S was obtained with a five-step procedure of translation and cross-cultural adaptation. All invited patients met the New York criteria for AS, and a total of 103 patients finally participated in this study...
July 27, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28745693/-efficiency-of-different-celecoxib-regimens-in-patients-with-active-axial-spondyloarthritis-results-of-the-4-week-pilot-open-label-comparative-single-center-study-aim
#2
I Z Gaydukova, К A Gamayunova, K D Dorogoykina, A P Rebrov
AIM: To compare the efficiency and safety of two celecoxib regimens in the short-term treatment of patients with axial spondyloarthritis (axSpA). SUBJECTS AND METHODS: Examinations were made in 40 patients with axSpA (the 2009 ASAS criteria; age, 38.5±12.1 years; 29 (72.5%) men; axSpA duration, 6.67±5.8 years; BASDAI ≥4.0), who were randomly divided into two groups: 1) 20 patients who received celecoxib 400 mg/day for 30 days; 2) 20 patients who took celecoxib 600 mg/day for 7 days, then the drug was continued at a dose of 200 mg/day for 1 month...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28737251/a-randomized-controlled-trial-to-study-the-efficacy-of-sulfasalazine-for-axial-disease-in-ankylosing-spondylitis
#3
Shefali Khanna Sharma, Vikas Kadiyala, Gsrsnk Naidu, Varun Dhir
AIM: To evaluate efficacy of sulfasalazine for axial ankylosing spondylosis. METHODS: 67 patients fulfilling the inclusion criteria were included and randomized into treatment and placebo group. RESULTS: Mean age in treatment group was 31 years (range: 17-60); placebo group was 30 years (18-46). Mean disease duration treatment group 8.4 years (range: 3-25) and placebo group was 8.3 years (3-19). Clinically significant improvement in ASDAS (ΔASDAS > 1...
July 24, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28736223/semaphorin-3a-in-ankylosing-spondylitis
#4
Hsien-Tzung Liao, Yuh-Feng Lin, Chung-Tei Chou, Chang-Youh Tsai
BACKGROUND/PURPOSE: To determine serum semaphorin 3A (Sema 3A) levels in ankylosing spondylitis (AS). METHODS: Serum Sema 3A was measured in 46 AS patients and 30 healthy controls (HCs). For the patients, we recorded demographic data, disease activity, functional index & global assessment, detected human leukocyte antigen-B27 (HLA-B27), and measured erythrocyte sedimentation rate (ESR) & C-reactive protein (CRP). RESULTS: Sema 3A was higher in AS patients than in HCs (3...
July 14, 2017: Journal of Microbiology, Immunology, and Infection, Wei Mian Yu Gan Ran za Zhi
https://www.readbyqxmd.com/read/28724442/impact-of-obesity-on-the-response-to-tumor-necrosis-factor-inhibitors-in-axial-spondyloarthritis
#5
Raphael Micheroli, Monika Hebeisen, Lukas M Wildi, Pascale Exer, Giorgio Tamborrini, Jürg Bernhard, Burkhard Möller, Pascal Zufferey, Michael J Nissen, Almut Scherer, Adrian Ciurea
BACKGROUND: Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). The aim of our study was to investigate the impact of different body mass index (BMI) categories on TNFi response in a large cohort of patients with axSpA. METHODS: Patients with axSpA within the Swiss Clinical Quality Management (SCQM) program were included in the current study if they fulfilled the Assessment in Spondyloarthritis International Society (ASAS) criteria for axSpA, started a first TNFi after recruitment, and had available BMI data as well as a baseline and follow-up visit at 1 year (±6 months)...
July 19, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28723759/determining-the-relationship-of-kinesiophobia-with-respiratory-functions-and-functional-capacity-in-ankylosing-spondylitis
#6
Göktuğ Er, Ender AngIn
Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease that affects the axial skeleton, causes inflammatory lower back pain, and structural and functional disorders, which affect quality of life negatively.The purpose of this study is to investigate the effects of kinesiophobia in AS on pulmonary function tests (PFTs) and functional performance.Thirty-one individuals with AS (n = 19 male, n = 12 female) who were suitable on the basis of the Modified New York (MNY) criteria were included in the study...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28711878/fat-mass-lowers-the-response-to-tumor-necrosis-factor-%C3%AE-blockers-in-patients-with-ankylosing-spondylitis
#7
Sebastián E Ibáñez Vodnizza, Michael T Nurmohamed, Ingrid M Visman, J Christiaan van Denderen, Willem F Lems, Francisca Jaime, Irene E van der Horst-Bruinsma
OBJECTIVE: Our main objective was to assess the relationship between body composition (BC) and response to tumor necrosis factor-α (TNF-α) blocker treatment in patients with ankylosing spondylitis (AS). Our secondary objective was to evaluate the change of BC after treatment, accounting for sex and age. METHODS: All included patients fulfilled the modified New York criteria for AS and were naive to TNF-α blocker. They were followed for at least 6 months after the start of etanercept or adalimumab...
July 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28661926/the-discriminative-values-of-the-bath-ankylosing-spondylitis-disease-activity-index-ankylosing-spondylitis-disease-activity-score-c-reactive-protein-and-erythrocyte-sedimentation-rate-in-spondyloarthritis-related-axial-arthritis
#8
Helen Hoi Lun Tsang, Ho Yin Chung
OBJECTIVES: The aims of this study were to determine the effectiveness of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP), Ankylosing Spondylitis Disease Activity Score-Erythrocyte Sedimentation Rate (ASDAS-ESR), and inflammatory markers in screening for axial-joint inflammation as detected by magnetic resonance imaging (MRI) and to find out factors that could affect scoring of the indices. METHODS: One hundred fifty-three Chinese spondyloarthritis patients were recruited...
August 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28659998/axial-spondyloarthritis-and-cigarette-smoking
#9
Irène Kona Kaut, Fatima Ezzhara Abourazzak, Essouri Jamila, Florine Awassi Sènami, Desiré Diketa, Harzy Taoufik
BACKGROUND: Smoking is one of the main environmental risk factors involved in several rheumatic diseases according to ACR 2014, it is included among the risk factors for severe axial spondyloarthritis. OBJECTIVES: The objective is to study the association between smoking and the activity of the disease, the functional impact and the severity of the axial spondyloarthritis. METHODS: It is a transversal study with a descriptive and analytical aim, during the period between January 2014 and December 2015 conducted in the department of rheumatology at the CHU Hassan II of Fes...
2017: Open Rheumatology Journal
https://www.readbyqxmd.com/read/28646368/tnf%C3%AE-blockers-followed-by-continuation-of-sulfasalazine-and-methotrexate-combination-a-retrospective-study-on-cost-saving-options-of-treatment-in-spondyloarthritis
#10
Aswin M Nair, P Sandhya, Bijesh Yadav, Debashish Danda
High cost deters continuous use of tumor necrosis factor α blockers (TNFi) in developing countries. The objective of this study was to evaluate outcome and expenditure incurred in Spondyloarthritis (SpA) patients beyond a year of follow-up after receiving four doses of infliximab (IFX) over and above background therapy of methotrexate (MTX) and sulfasalazine (SSZ) combination. Electronic medical records were screened for patients with SpA satisfying the Assessment of Spondyloarthritis International Society (ASAS) criteria between 2008 and 2014...
June 23, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28631697/-changes-in-the-serum-concentrations-of-adhesion-molecules-and-vascular-endothelial-growth-factor-in-active-ankylosing-spondylitis-patients-taking-amtolmetin-guacil-results-of-a-56-week-prospective-%C3%B0-%C3%B1-%C3%B0%C2%B5n-label-controlled-observational-study
#11
I Z Gaydukova, E V Khondkaryan, A V Aparkina, A P Rebrov
AIM: To estimate changes in the concentrations of adhesion molecules and vascular endothelial growth factor A after 30-day additional use of amtolmetin guacil (AMG) in patients with active ankylosing spondylitis (AS) who were unresponsive to previous one-year treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). SUBJECTS AND METHODS: 20 patients with active AS who had not reached a BASDAI score <4.0 at week 52 of NSAID therapy and 10 healthy individuals matched for cardiovascular risk factors were examined...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28631696/-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-two-stages-of-disease
#12
D G Rumyantseva, T V Dubinina, A B Demina, O A Rumyantseva, E M Agafonova, A V Smirnov, Sh F Erdes
AIM: To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA). SUBJECTS AND METHODS: A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis. The mean age at the time of inclusion in the study was 28.1±5.5 years; the mean disease duration was 24...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28630526/discriminating-value-of-calprotectin-in-disease-activity-and-progression-of-nonradiographic-axial-spondyloarthritis-and-ankylosing-spondylitis
#13
Jinxian Huang, Zhihua Yin, Guoxiang Song, Shengjin Cui, Jinzhao Jiang, Lijun Zhang
It has been controversial whether ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA) are separate or different phases of radiographic progression. We determined that serum calprotectin level (ng/ml) was higher in AS (15.30 ± 6.49) and nr-axSpA (17.76 ± 8.59) patients than in healthy individuals (7.40 ± 2.67). No difference was observed in calprotectin level between these two groups. Elevated calprotectin was positively correlated with ESR, CRP, BASDAI, and ASDAS as well as SPARCC scoring and had no correlation with BASFI and mSASSS...
2017: Disease Markers
https://www.readbyqxmd.com/read/28605535/muscle-wasting-in-male-tnf-%C3%AE-blocker-na%C3%A3-ve-ankylosing-spondylitis-patients-a-comparison-of-gender-differences-in-body-composition
#14
Sebastián Ibáñez Vodnizza, Ingrid M Visman, Christiaan van Denderen, Willem F Lems, Francisca Jaime, Michael T Nurmohamed, Irene E van der Horst-Bruinsma
Objective.: To assess gender differences in body composition (BC) in a cohort of AS patients naïve to TNF-α blockers. Methods.: Patients included fulfilled the Modified New York criteria for AS. Demographic information and disease activity measures (ASDAS and BASDAI) were reported. BC was measured by whole body DXA. Body fat percentage (BF%), fat mass index (FMI), fat free mass index (FFMI) and android/gynoid fat ratio were reported and compared between men and women and with the reference population (percentiles)...
June 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/28569568/performance-of-the-classification-criteria-in-patients-with-late-onset-axial-spondyloarthritis
#15
Louise T Bendahan, Natália P Machado, Jamille G Mendes, Thauana L Oliveira, Marcelo M Pinheiro
AIM: To evaluate the performance of four different classification criteria for spondyloarthritis (SpA) in patients with late-onset symptoms and to compare the clinical, laboratory and radiographic outcomes among the patients with symptoms before and after 45 years of age. PATIENTS AND METHODS: A total of 329 patients with SpA were enrolled in this prospective cohort. Patients with psoriatic arthritis, reactive arthritis, colitis associated arthritis and peripheral or undifferentiated SpA were excluded...
June 1, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28539676/results-from-polish-spondyloarthritis-initiative-registry-polspi-methodology-and-data-from-the-first-year-of-observation
#16
Zofia Guła, Tacjana Barczyńska, Marek Brzosko, Jerzy Gąsowski, Sławomir Jeka, Katarzyna Jodłowska-Cicio, Beata Kwaśny-Krochin, Piotr Leszczyński, Łukasz Lubiński, Katarzyna Łosińska, Katarzyna Pawlak-Buś, Hanna Przepiera-Będzak, Włodzimierz Samborski, Małgorzata Schlabs, Maciej Siedlar, Dorota Sikorska, Jerzy Świerkot, Małgorzata Węgierska, Piotr Wiland, Mariusz Korkosz
OBJECTIVES: Report on one-year results from the Polish Spondyloarthritis Initiative registry (PolSPI), containing the cross-sectional analysis of clinical and imaging data as well as database methodology. MATERIAL AND METHODS: The PolSPI registry includes patients with axial (axSpA) and peripheral (perSpA) spondyloarthritis according to ASAS classification criteria, and/or patients with ankylosing spondylitis according to modified New York criteria, psoriatic arthritis according to CASPAR criteria, arthropathy in inflammatory bowel disease, reactive arthritis, juvenile spondyloarthritis or undifferentiated spondyloarthritis...
2017: Reumatologia
https://www.readbyqxmd.com/read/28516874/long-term-effects-of-interleukin-17a-inhibition-with-secukinumab-in-active-ankylosing-spondylitis-3-year-efficacy-and-safety-results-from-an-extension-of-the-phase-3-measure-1-trial
#17
Xenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, Jürgen Braun, James C Wei, Eumorphia Maria Delicha, Zsolt Talloczy, Brian Porter
OBJECTIVES: Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3 MEASURE 1 trial. Here, we report efficacy and safety after 3 years of treatment. METHODS: AS subjects completing 2 years of treatment every 4 weeks with subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) entered a separate 3-year extension study (NCT01863732)...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28514405/-stable-high-interleukin-17a-concentration-in-patients-with-ankylosing-spondylitis-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-during-a-year
#18
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan
AIM: To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. SUBJECTS AND METHODS: Examinations were made in 30 patients (22 (73.3%) men) aged 38.35±9.19 years with AS (modified New-York criteria, BASDAI ≥4.0; AS duration, 11.4±9.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1±7.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg/kg body weight during a year according to the recommended regimen...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28507445/evaluation-of-fatigue-and-its-correlation-with-quality-of-life-index-anxiety-symptoms-depression-and-activity-of-disease-in-patients-with-psoriatic-arthritis
#19
Claudio Carneiro, Mario Chaves, Gustavo Verardino, Ana Paula Frade, Pedro Guimaraes Coscarelli, Washington Alves Bianchi, Marcia Ramos-E-Silva, Sueli Carneiro
BACKGROUND: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue. OBJECTIVES: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity. PATIENTS AND METHODS: This cross-sectional study was performed on outpatients with psoriatic arthritis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28498975/sustained-efficacy-safety-and-patient-reported-outcomes-of-certolizumab-pegol-in-axial-spondyloarthritis-4-year-outcomes-from-rapid-axspa
#20
Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar
Objective.: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods.: RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease...
May 12, 2017: Rheumatology
keyword
keyword
116433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"